- Home
- GDV vs CNTA Comparison
GDV vs CNTA Comparison
Compare GDV & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDV
- CNTA
- Stock Information
- Founded
- GDV 2003
- CNTA 2020
- Country
- GDV United States
- CNTA United Kingdom
- Employees
- GDV N/A
- CNTA N/A
- Industry
- GDV Investment Managers
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- GDV Finance
- CNTA Health Care
- Exchange
- GDV Nasdaq
- CNTA Nasdaq
- Market Cap
- GDV 2.2B
- CNTA 1.6B
- IPO Year
- GDV N/A
- CNTA 2021
- Fundamental
- Price
- GDV $26.63
- CNTA $14.07
- Analyst Decision
- GDV
- CNTA Strong Buy
- Analyst Count
- GDV 0
- CNTA 10
- Target Price
- GDV N/A
- CNTA $28.78
- AVG Volume (30 Days)
- GDV 186.0K
- CNTA 1.2M
- Earning Date
- GDV 01-01-0001
- CNTA 08-12-2025
- Dividend Yield
- GDV 5.81%
- CNTA N/A
- EPS Growth
- GDV N/A
- CNTA N/A
- EPS
- GDV N/A
- CNTA N/A
- Revenue
- GDV N/A
- CNTA $15,000,000.00
- Revenue This Year
- GDV N/A
- CNTA N/A
- Revenue Next Year
- GDV N/A
- CNTA N/A
- P/E Ratio
- GDV N/A
- CNTA N/A
- Revenue Growth
- GDV N/A
- CNTA 118.88
- 52 Week Low
- GDV $18.04
- CNTA $8.46
- 52 Week High
- GDV $23.00
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- GDV 78.52
- CNTA 60.47
- Support Level
- GDV $24.57
- CNTA $12.74
- Resistance Level
- GDV $25.29
- CNTA $14.27
- Average True Range (ATR)
- GDV 0.29
- CNTA 0.66
- MACD
- GDV 0.12
- CNTA 0.12
- Stochastic Oscillator
- GDV 98.10
- CNTA 85.57
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.